Michael A Pfeffer, Tia C L Kohs, Helen H Vu, Kelley R Jordan, Jenny Si Han Wang, Christina U Lorentz, Erik I Tucker, Cristina Puy, Sven R Olson, Thomas G DeLoughery, Monica T Hinds, Ravi S Keshari, David Gailani, Florea Lupu, Owen J T McCarty, Joseph J Shatzel
BACKGROUND: Despite the ubiquitous utilization of central venous catheters in clinical practice, their use commonly provokes thromboembolism. No prophylactic strategy has shown sufficient efficacy to justify routine use. Coagulation factors FXI (factor XI) and FXII (factor XII) represent novel targets for device-associated thrombosis, which may mitigate bleeding risk. Our objective was to evaluate the safety and efficacy of an anti-FXI mAb, gruticibart (AB023), in a prospective, single-arm study of patients with cancer receiving central line placement...
November 16, 2023: Arteriosclerosis, Thrombosis, and Vascular Biology